WallStSmart

Hecla Mining Company (HL)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Hecla Mining Company generates 2847% more annual revenue ($1.63B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 16.8%. HL trades at a lower P/E of 21.0x. HL earns a higher WallStSmart Score of 70/100 (B-).

HL

Strong Buy

70

out of 100

Grade: B-

Growth: 10.0Profit: 8.0Value: 5.3Quality: 9.0
Piotroski: 6/9Altman Z: 2.55

VMET

Buy

58

out of 100

Grade: C

Growth: 10.0Profit: 8.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HLUndervalued (+29.6%)

Margin of Safety

+29.6%

Fair Value

$23.20

Current Price

$16.33

$6.87 discount

UndervaluedFair: $23.20Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HL4 strengths · Avg: 9.8/10
Operating MarginProfitability
55.5%10/10

Strong operational efficiency at 55.5%

Revenue GrowthGrowth
100.4%10/10

Revenue surging 100.4% year-over-year

EPS GrowthGrowth
952.0%10/10

Earnings expanding 952.0% YoY

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

VMET5 strengths · Avg: 9.8/10
Profit MarginProfitability
58.4%10/10

Keeps 58 of every $100 in revenue as profit

Operating MarginProfitability
90.6%10/10

Strong operational efficiency at 90.6%

Revenue GrowthGrowth
594.0%10/10

Revenue surging 594.0% year-over-year

EPS GrowthGrowth
573.0%10/10

Earnings expanding 573.0% YoY

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Areas to Watch

HL1 concerns · Avg: 2.0/10
PEG RatioValuation
5.642/10

Expensive relative to growth rate

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Market CapQuality
$1.26B3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : HL

The strongest argument for HL centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 16.8% and operating margin at 55.5%. Revenue growth of 100.4% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.

Bear Case : HL

The primary concerns for HL are PEG Ratio.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VMET is growing revenue faster at 594.0% — sustainability is the question.

HL generates stronger free cash flow (155M), providing more financial flexibility.

Monitor OTHER PRECIOUS METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HL scores higher overall (70/100 vs 58/100), backed by strong 16.8% margins and 100.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hecla Mining Company

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Hecla Mining Company discovers, acquires, develops and produces precious and base metal properties in the United States and internationally. The company is headquartered in Coeur d'Alene, Idaho.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing cutting-edge therapeutics for serious diseases, leveraging its proprietary metalloenzyme-based technology platform. The company is committed to addressing significant unmet medical needs in fungal infections and oncology, positioning itself as a leader in therapeutic innovation. With a diverse pipeline bolstered by strategic collaborations and a strong intellectual property portfolio, Viamet is well-prepared to advance its clinical initiatives and enhance shareholder value, aiming to redefine treatment approaches in its specialized therapeutic areas.

Want to dig deeper into these stocks?